Mirabegron: A new option in treating overactive bladder

被引：1

作者：

Turpen, Heidi Camus ^{[1
]}

Zimmern, Philippe E. ^{[1
]}

机构：

[1] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA

来源：

JAAPA-JOURNAL OF THE AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS | 2015年 / 28卷 / 11期

关键词：

overactive bladder; mirabegron; detrusor muscle; voiding frequency; beta(3) adrenoceptor agonist; incontinence; BETA(3)-ADRENOCEPTOR AGONIST; EFFICACY; THERAPY; SAFETY; INCONTINENCE; PHASE-3;

D O I：

10.1097/01.JAA.0000472558.50124.7e

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Antimuscarinic medications have long been the mainstay of drug treatment for overactive bladder. This article describes mirabegron, one of a new class of agents that relaxes the detrusor muscle directly via a beta 3 adrenoceptor agonist. Mirabegron's efficacy on frequency, urgency, and urge incontinence was tested in several trials before its wide clinical introduction. However, caution is still needed as data are lacking on the drug's efficacy and safety in frail older adults and for long-term therapy.

引用

页码：16 / 18

页数：2

共 15 条

[1] The standardisation of terminology in lower urinary tract function: Report from the standardisation sub-committee of the International Continence Society (Reprinted from Neurourology and Urodynamics, vol 21, pg 167-178, 2002)
Abrams, P
Cardozo, L
Fall, M
Griffiths, D
Rosier, P
Ulmsten, U
Van Kerrebroeck, P
Victor, A
Wein, A
[J]. UROLOGY, 2003, 61 (01) : 37 - 49
[2] Selective β3-Adrenoceptor Agonists for the Treatment of Overactive Bladder
Andersson, Karl-Erik
Martin, Nancy
Nitti, Victor
[J]. JOURNAL OF UROLOGY, 2013, 190 (04) : 1173 - 1180
[3] Antimuscarinics for treatment of overactive bladder
Andersson, KE
[J]. LANCET NEUROLOGY, 2004, 3 (01) : 46 - 53
[4] Combined behavioral and drug therapy for urge incontinence in older women
Burgio, KL
Locher, JL
Goode, PS
[J]. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2000, 48 (04) : 370 - 374
[5] Randomized Double-blind, Active-controlled Phase 3 Study to Assess 12-Month Safety and Efficacy of Mirabegron, a β3-Adrenoceptor Agonist, in Overactive Bladder
Chapple, Christopher R.
Kaplan, Steven A.
Mitcheson, David
Klecka, Jiri
Cummings, Jana
Drogendijk, Ted
Dorrepaal, Caroline
Martin, Nancy
[J]. EUROPEAN UROLOGY, 2013, 63 (02) : 296 - 305
[6] National Community Prevalence of Overactive Bladder in the United States Stratified by Sex and Age
Coyne, Karin S.
Sexton, Chris C.
Vats, Vasudha
Thompson, Christine
Kopp, Zoe S.
Milsom, Ian
[J]. UROLOGY, 2011, 77 (05) : 1081 - 1087
[7] A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicentre Study to Assess the Efficacy and Safety of the β3 Adrenoceptor Agonist, Mirabegron, in Patients With Symptoms of Overactive Bladder
Herschorn, Sender
Barkin, Jack
Castro-Diaz, David
Frankel, Jeffrey M.
Espuna-Pons, Montserrat
Gousse, Angelo E.
Stoelzel, Matthias
Martin, Nancy
Gunther, Adrie
Van Kerrebroeck, Philip
[J]. UROLOGY, 2013, 82 (02) : 313 - 320
[8] Efficacy and Tolerability of Mirabegron, a β3-Adrenoceptor Agonist, in Patients with Overactive Bladder: Results from a Randomised European-Australian Phase 3 Trial
Khullar, Vik
Amarenco, Gerard
Angulo, Javier C.
Cambronero, Javier
Hoye, Kjetil
Milsom, Ian
Radziszewski, Piotr
Rechberger, Tomasz
Boerrigter, Peter
Drogendijk, Ted
Wooning, Marianne
Chapple, Christopher
[J]. EUROPEAN UROLOGY, 2013, 63 (02) : 283 - 295
[9] The effect of mirabegron, a potent and selective β3-adrenoceptor agonist, on the pharmacokinetics of CYP2D6 substrates desipramine and metoprolol
Krauwinkel, Walter
Dickinson, James
Schaddelee, Marloes
Meijer, John
Tretter, Reiner
van de Wetering, Jeroen
Strabach, Gregory
van Gelderen, Marcel
[J]. EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2014, 39 (01) : 43 - 52
[10] Perspectives on mirabegron in the treatment of overactive bladder syndrome: A new beta-3 adrenoceptor agonist
Kuei, Chia-Hao
Peng, Chung-Hsin
Liao, Chun-Hou
[J]. UROLOGICAL SCIENCE, 2015, 26 (01) : 17 - 23

← 1 2 →